Neurobiological basis for the use of botulinum toxin in pain therapy

Journal of Neurology, Supplement

Volumn 251, Issue 1, 2004, Pages 1-7

  Mense, S ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Analgesia; Contracture; Muscle pain; Muscle tone; Spasm

Indexed keywords

ACETYLCHOLINE; ADENOSINE TRIPHOSPHATE; ANALGESIC AGENT; BOTULINUM TOXIN; BRADYKININ; NEUROPEPTIDE; NORADRENALIN;

ANALGESIC ACTIVITY; CHOLINERGIC NERVE; DRUG MECHANISM; DYSTONIA; EXOCYTOSIS; HUMAN; MUSCLE CELL; MUSCLE CONTRACTURE; MUSCLE ISCHEMIA; MUSCLE RELAXATION; MUSCLE SPASM; MUSCLE TONE; MYOFASCIAL PAIN; NERVE ENDING; NEUROBIOLOGY; NOCICEPTIVE RECEPTOR; PAIN; PH; PRESYNAPTIC MEMBRANE; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SEROTYPE; SYNAPSE VESICLE;

ANALGESIA; ANIMALS; ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; DYSTONIA; HUMANS; MODELS, NEUROLOGICAL; MUSCLE CONTRACTION; NEUROMUSCULAR JUNCTION; PAIN; SPASM;

EID: 1542344497     PISSN: 09391517     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Adreani CM, Kaufman MP (1998) Effect of arterial occlusion on responses of group III and IV afferents to dynamic exercise. J appl Physiol 84: 1827-1833
2. Alo KM, Yland MJ, Kramer DL, et al. (1997) Botulinum toxin in the treatment of myofascial pain. The Pain Clinic 10:107-116
3. Aoki K (2001) Pharmacology and immunology of botulinum toxin serotypes. J Neurol 248(Suppl 1):3-10
4. Aoki K (2003) Evidence for antinociceptive activity of botulium toxin type A in pain management. Headache 43: (Suppl):S9-S15
5. Argoff CE (2002) A focused review on the use of botulinum toxins for neuropathic pain. Clin J Pain 18:S177-S181
6. Argoff CE (2003) The use of botulinum toxins for chronic pain and headaches. Curr Treatm Options Neurol 5:483-492
7. Blasi J, Chapman ER, Link E, et al. (1993) Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 265:160-163
8. Brin MF, Fahn S, Moskowitz C, et al. (1988) Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Adv Neurol 50:599-608
9. 2-Messung in der verspannten Rückenmuskulatur (m erector spinae). Z Rheumatol 49:208-216
10. Burnstock G (2000) P2X receptors in sensory neurones. Br J Anaesth 84: 476-488
11. Burnstock G, Wood JN ( 1996) Purinergic receptors: their role in nociception and primary afferent neurotransmission. Curr Opin Neurobiol 6:526-532
12. Chalkiadaki A, Rohr UP, Hefter H (2001) Frühe Schmerzreduktion in der Therapie von Spastik nach einmaliger Botulinustoxin-A-Injektion. Dtsch Med Wochenschr 126:1361-1364
13. Cheshire WP, Abashian SW, Mann JD (1994) Botulinum toxin in the treatment of myofascial pain syndrome. Pain 59:65-69
14. Dunne JW, Heye N, Dunne SL (1995) Treatment of chronic limb spasticity with botulinum toxin. J Neurol Neurosurg Psychiatry 58:232-235
15. Filippi GM, Errico P, Santarelli R, et al. (1993) Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol 113:400-404
16. Foster L, Clapp L, Erickson M, Jabbari B (2001) Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology 56: 1290-1293
17. Haouzi P, Hill JM, Lewis BK, Kaufman MP (1999) Responses of group III and IV muscle afferents to distension of the peripheral vascular bed. J Appl Physiol 87:545-553
18. Headley BJ (1990) EMG and myofascial pain. Clin Managern 10:43-46
19. + blockade. Neuron 37:75-84
20. Jänig W, Häbler H-J (2000) Sympathetic nervous system: contribution to chronic pain. In: Sandkühler J, Bromm B, Gebhart GF (eds) Progress in Brain Res 129:451-468, Elsevier
21. Keim S, Gerats G, Chalkiadaki A, Hefter H (2001) Reduction of pain and muscle spasms by botulinum toxin A. Nervenarzt 72:302-306
22. Lund JP, Donga R, Widmer CG, Stohler CS (1991) The pain-adaptation model: a discussion of the relationship between chronic musculoskeletal pain and motor activity. Can J Physiol Pharmacol 69:683-694
23. Marchettini P, Simone DA, Caputi G, Ochoa JL (1996) Pain from excitation of identified muscle nociceptors in humans. Brain Res 40:109-116
24. Mense S, Meyer H (1985) Different types of slowly conducting afferent units in cat skeletal muscle and tendon. J Physiol 363:403-417
25. Mense S, Simons DG (2001) Muscle Pain. Understanding its nature, diagnosis, and treatment Lippincott, Williams and Wilkins, Philadelphia
26. Mense S, Stahnke M (1983) Responses in muscle afferent fibres of slow conduction velocity to contractions and ischaemia in the cat. J Physiol 342: 383-397
27. Porta M, Perretti A, Gamba M, Luccarelli G, Fornari M (1998) The rationale and results of treating muscle spasm and myofascial syndromes with botulinum toxin type A. Pain Digest 8:346-352
28. Reinöhl J, Hoheisel U, Unger T, Mense S (2003) Adenosine triphosphate as a stimulant for nociceptive and non-nociceptive muscle group IV receptors in the rat. Neurosci Lett 338:25-28
29. Resales RL, Arimura K, Ikenaga S, Osame M (1996) Extrafusal and intrafusal muscle effects in experimental botulinum toxin A injection. Muscle Nerve 19:488-496
30. Simons DG (1996) Clinical and etiological update of myofascial pain from trigger points. J Musculoskeletal Pain 4:93-121
31. Simons DG, Mense S (1998) Understanding and measurement of muscle tone as related to clinical muscle pain. Pain 75:1-17
32. Stokes M, Young A (1984) The contribution of reflex inhibition to arthrogenic muscle weakness. Clin Sci 67: 7-14
33. Sutherland SP, Cook SP, McCleskey EW (2000) Chemical mediators of pain due to tissue damage and ischemia. Prog Brain Res 129:21-38
34. Tarsy D, First ER (1999) Painful cervical dystonia: clinical features and response to treatment with botulinum toxin. Mov Disord 14:1043-1045
35. Voller B, Sycha T, Gustorff B, et al. (2003) A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A. Neurology 61:940-944
36. Wissel J, Muller J, Dressnandt J, et al. (2000) Management of spasticity associated pain with botulinum toxin AJ Pain Symptom Manage 20:44-49